Amlexanox

Drug Profile

Amlexanox

Alternative Names: Aftaid; Aphthasol; Aptheal; Apthera; CHX 3673; Miraftil; OraDisc A; OraRinse™

Latest Information Update: 13 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Takeda
  • Developer Pharmascience; ULURU
  • Class Aminopyridines; Antiallergics; Small molecules
  • Mechanism of Action Histamine release inhibitors; Leukotriene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Aphthous stomatitis

Highest Development Phases

  • Market Withdrawal Aphthous stomatitis
  • Discontinued Atopic dermatitis; Mouth disorders; Mucositis

Most Recent Events

  • 05 Jul 2017 Amlexanox topical patch (OraDisc™ A) is available for licensing in USA as of 05 Jul 2017. https://www.uluruinc.info/
  • 05 Aug 2016 Meda has been acquired by Mylan
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top